Post-Transplant Thrombotic Microangiopathy with Underlying CFHR1/CFHR3 Deletion: Response to Eculizumab (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO1171; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Tacrolimus (Tac) was switched to cyclosporine as he was not a candidate for belatacept (- EBV status). Complement genetic mutations are identified in up to 60–70% of aHUS cases. Differentiating complement-mediated TMA from other causes is critical, as it guides targeted therapy and beneficial."
Post-transplantation • Antibody-mediated Rejection • Complement-mediated Rare Disorders • Fibrosis • Immunology • Reperfusion Injury • Transplantation • CFHR3 • HP
|
|
Drew N. Graydon; Vraj Patel; Iris J. Lee; Kanika Aggarwal
|